Doc's note: On its face, Tesla looks like a car company. But for years, it has been clear that Elon Musk has positioned Tesla as an AI company.

But, as Joel Litman – from our corporate affiliate Altimetry – explains, this tech darling is showing cracks and putting investors at risk...

The "Magnificent Seven" are experiencing something of a reckoning...

Investors aren't satisfied with some of the market's biggest tech stocks.

Folks punished Google parent Alphabet (GOOGL) for spending too much on AI... and in the same breath, took aim at Tesla (TSLA) for spending too little.

The electric-vehicle ("EV") leader has trailed its Mag Seven peers in terms of capital-expenditure ("capex") spending. And investors have bid the stock down about 25% as a result.

That dip might seem like a tempting opportunity to buy in. After all, Tesla is still a member of the AI elite.

But as we'll cover today, the market still expects far too much from Elon Musk's EV darling. And a key gap keeps widening... putting investors' capital at risk.

Tesla's restrained spending would matter less if its valuation were lower...

We explained yesterday that the EV maker has spent just $2.5 billion of its planned $25 billion AI commitment so far this year.

That pales in comparison with its Mag Seven peers' projected $725 billion in 2026 capex spending.

At the same time, shares trade at roughly 167 times forward earnings.

That makes Tesla the second-most-expensive stock in the S&P 500... and by far the priciest member of the Mag Seven. It's roughly five times more costly than Apple (AAPL), the second-most-expensive company in the group.

So we have an expensive stock... and a business that's still ramping up its AI spending. That doesn't sound like a recipe for success.

But despite all of that, investors think Tesla's business will soar from here...

We can see this through our Embedded Expectations Analysis ("EEA") framework.

The EEA starts by looking at a company's current stock price. From there, we can calculate what the market expects from the company's future cash flows. We then compare that with our own cash-flow projections.

In short, it tells us how well a company has to perform in the future to be worth what the market is paying for it today.

Tesla's Uniform return on assets ("ROA") peaked near 30% in 2022, more than twice the 12% market average. Returns plummeted to just 6% by 2025.

And yet, the market thinks ROA will skyrocket to 44% by 2030. That would be an all-time high...

That wouldn't be only a rebound... It would make Tesla far more profitable than it has ever been.

Tesla's ROA has plummeted in recent years. Meanwhile, the company is tripling its capex to $25 billion this year. This type of spending will make generating higher returns even harder. The market is pricing in a historic recovery while returns are declining.

Tesla CEO Elon Musk's bigger AI story now sits elsewhere...

Musk is still spending heavily on AI. The difference is where that capital is going.

SpaceX (SPCX) raised roughly $100 billion through its June IPO and subsequent bond sale, giving Musk a much larger pool of money for orbital data centers and large-scale computing projects. Its business spans rockets, satellite connectivity, and AI infrastructure.

Much of the capital raised in the IPO is already spoken for. SpaceX has disclosed computing power deals with Google and Anthropic, and its bond proceeds are marked for AI infrastructure.

All of this spending will create winners across the AI supply chain. Chipmakers, server manufacturers, networking firms, and data-center suppliers will benefit from SpaceX's funding... long before Tesla proves that its robotaxis and humanoid robots are worth investors' support.

Tesla's stock valuation assumes it'll be the company to carry the torch of Musk's AI ambitions. However, with another major AI player under the CEO's belt and hyperscaler capex spending reaching new heights, Tesla is looking less likely to catch up in the race.

Regards,

Joel Litman

Editor's note: On Thursday, Joel is going live to detail a small group of stocks that could benefit from a massive new venture from Musk. This next move is backed by President Trump and the White House. And it could soon grant Elon "veto power" over the entire AI industry, deciding who wins or loses.

Click here to make sure you don't miss it.

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top